For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-cancer-janus-kinase-inhibitors-market-opportunity-and-clinical-trial-insight-2023.php
Table of Contents
1. Prologue to JAK/STAT Pathway
1.1 Overview
1.2 Categorization of JAK/STAT Inhibitors in Cancer Therapeutics
2. Role of JAK/STAT Pathway in Tumor Formation
3. JAK/STAT Inhibitors: Modern Therapeutics for Effective Cancer Management
4. Understanding the Targets for Inhibition: An Insight into JAK and STAT Proteins
4.1 Structure and Significance
4.1.1 Janus Kinases: A Novel Cytokine Receptor
4.1.2 STAT Proteins: The Signal Generators for Transcription
4.2 Importance of Modulation of JAK/STAT in a Healthy Cell
5. Mechanism of Action of JAK/STAT Inhibitors
6. Identification of Active Target in Tumor Cells for JAK/STAT Inhibition
6.1 Cell Based Assays
6.2 Biochemical Assays
7. Need and Superiority of JAK/STAT Inhibitors: Its Importance in Modern Cancer Therapy
8. JAK/STAT Inhibitors in Cancer Therapy
8.1 Hematological Malignancies
8.1.1 Myelofibrosis
8.1.2 Acute Lymphoblastic Leukemia
8.1.3 Polycythemia Vera
8.1.4 Primary thrombocythemia
8.2 Solid Tumors
8.2.1 Lung Cancer
8.2.2 Ovarian Cancer
8.2.3 Breast Cancer
8.2.4 Pancreatic Cancer
8.2.5 Hepatocellular Carcinoma
8.2.6 Colorectal cancer
8.2.7 Head and Neck Squamous Cell Carcinoma
8.2.8 Prostate Cancer
8.2.9 Glioblastoma
8.2.10 Other Solid Tumors
9. Cancer JAK/STAT Inhibitor Drugs
9.1 Approved Drugs
9.1.1 Ruxolitinib
9.2 Promising Candidates in the Clinical Pipeline
9.2.1 Momelotinib
9.2.2 Lestaurtinib
9.2.3 Pacritinib
10. Global Cancer JAK/STAT Inhibitor Market Outlook
10.1 Current Scenario
10.2 Clinical Pipeline Overview
11. Global Cancer JAK/STAT Inhibitor Therapy Price Analysis
11.1 Analyzing the Cost of Available JAK/STAT Inhibitor
11.2 Comparative Price Analysis of JAK/STAT Inhibitors and Best Available Therapy
11.3 Comparative Price Analysis of JAK/STAT Inhibitors and Conventional Cancer Therapies
11.4 Comparative Price Analysis of JAK/STAT Inhibitors and Newly Approved Anti-Cancer Therapeutics
12. Global Cancer JAK/STAT Inhibitor Market Dynamics
12.1 Favorable Factors for Cancer JAK/STAT Inhibitors Market
12.1.1 Elevation in Disease Burden
12.1.2 Unmet Medical Need
12.1.3 Advancement in Technology
12.1.4 Strong Clinical Pipeline
12.1.5 Orphan Drug Status to JAK/STAT Inhibitors
12.1.6 Commercial Success of Ruxolitinib
12.2 Market challenges for Cancer JAK/STAT Inhibitors
12.2.1 Scientific Limitations and the Number of Side Effects
12.2.2 Clinical Hold on Pacritinib
12.2.3 Tedious approval process
13. Global Cancer JAK/STAT Inhibitor Market Future Outlook
14. Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-III
14.7 Preregistration
15. Marketed Cancer Janus Kinase Inhibitors Clinical Insight by Company
15.1 Ruxolitinib (Jakafi and Jakavi)
16. Suspended Cancer Janus Kinase Inhibitors in Clinical Pipeline by Company and Phase
16.1 No Development Reported
16.2 Discontinued
17. Competitive Landscape
17.1 Abbott Laboratories
17.2 Asana Biosciences
17.3 Astra Zeneca
17.4 Celon Pharmaceuticals
17.5 Dynamic Pharma
17.6 Eli Lilly
17.7 Gilead Sciences
17.8 Hanmi Pharmaceuticals
17.9 Incyte
17.10 Kyowa Hakko
17.11 Moleculin
17.12 Pfizer
17.13 PIQUR Therapeutics
17.14 Portola Pharmaceuticals
17.15 S*BIO
Figure 1-1: Conventional Approaches for Treating Cancer
Figure 1-2: Major Limitations of Conventional Cancer Therapies
Figure 1-3: Modern Approach in Cancer Therapy
Figure 1-4: Major Types of Cancer Treatment Modalities
Figure 1-5: Categorization of JAK Inhibitors in Targeted Therapies
Figure 3-1: Advanced Approaches for the Development of JAK/STAT Inhibitors
Figure 4-1: Architecture of the Structure of Janus Kinase
Figure 4-2: Cis Mode of Activation of Janus Kinase
Figure 4-3: Trans Mode of Activation of Janus Kinase
Figure 4-4: Architecture of the Structure of STAT Proteins
Figure 4-5: Activation of STAT Proteins
Figure 4-6: Natural Inhibitors of JAK/STAT Signaling Pathway
Figure 5-1: JAK/STAT Signaling Pathway in Normal Human Cell
Figure 5-2: JAK/STAT Pathway in Hematological Cancers
Figure 5-3: Mechanism of Action of JAK inhibitors
Figure 6-1: Technologies Used For Diagnosing JAK/STAT Pathway in Tumor Cells
Figure 7-1: Advanced Features of JAK/STAT Inhibitors in Cancer Therapy
Figure 8-1: JAK/STAT Mutations in Hematological Malignancies
Figure 9-1: Target and Effects of Ruxolitinib
Figure 9-2: Impact of Ruxolitinib on Change in Mean Spleen Size
Figure 10-1: Global Prevalence – Myelofibrosis Patients (Numbers), 2015-17
Figure 10-2: Global Prevalence – Polycythemia Vera Patients (Numbers), 2015-17
Figure 10-3 Global Prevalence – Primary Thrombocythemia Patients (Numbers), 2015-17
Figure 10-4 : Global- Ruxolitinib Revenue for Myelofibrosis (US$ Million), 2015-2017
Figure 10-5: Global – Ruxolitinib Revenue for Polycythemia Vera (US$ Million), 2015-2017
Figure 10-6: Global- Ruxolitinib Revenue for Primary Thrombocythemia (US$ Million), 2015-2017
Figure 10-7: Global- Ruxolitinib Revenue by Hematological Malignancies (%), 2016
Figure 10-8: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
Figure 10-9: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 10-10: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
Figure 10-11: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 11-1: Ruxolitinib andndash; Average Per Tablet and Packet Cost Analysis (US$)
Figure 11-2: Ruxolitinib andndash; Average and Lifetime Treatment Cost Analysis (US$)
Figure 11-3: Global- Average Price of Ruxolitinib Treatment (US$/Month), 2015-2017
Figure 11-4: Survival Rate of Myelofibrosis Patients Undergoing Ruxolitinib Treatment v/s Best Available Therapy
Figure 11-5: Global – Average Lifetime Expenditure of Myelofibrosis Patient (US$)
Figure 11-6: Global – Average Lifetime Drug and Resource Cost (US$)
Figure 11-7: Global – Average Cost of Complete Treatment of Myelofibrosis Patient (US$)
Figure 11-8: Quality Adjusted Life Years for Ruxolitinib and Best Available Therapy for Myelofibrosis
Figure 11-9: Average Cost of JAK/STAT Inhibitors and Conventional Therapies for Cancer (US$/Month)
Figure 11-10: Complete Treatment Cost of JAK/STAT Inhibitors and Monoclonal Antibody Drug (US$)
Figure 11-11: Treatment Cost of JAK/STAT Inhibitors and CAR-T Cell Therapy for Cancer (US$)
Figure 11-12: Treatment Cost of JAK/STAT Inhibitors and Other Small Molecule Cancer Drugs (US$)
Figure 12-1: Global andndash; Cancer JAK/STAT Inhibitor Market Drivers
Figure 12-2: Global – Challenges for Cancer JAK/STAT Inhibitors Market
Figure 13-1: Global- Cancer JAK/STAT Inhibitors Market Opportunity (US$ Billion), 2018-2023
Table 2-1: JAK Mutations in Cancers
Table 2-2: STAT Mutations in Cancers
Table 11-1: Ruxolitinib Price Analysis
